BioCentury
ARTICLE | Finance

Program or platform?

Debating whether Alnylam's discontinued programs impact the rest of its pipeline

October 10, 2016 7:00 AM UTC

The slashing of $3.6 billion from Alnylam Pharmaceuticals Inc.'s market cap in a little more than a week suggests the markets are not comfortable with the company's argument that problems from two dropped programs will not affect the rest of the pipeline.

It doesn't help that the company has not yet had time to analyze the causes of an imbalance of deaths that caused it to discontinue revusiran late on Wednesday, or the efficacy data that contributed to a DMC's conclusion that the risk-benefit ratio was no longer favorable in familial amyloidotic cardiomyopathy (FAC), a form of transthyretin (TTR)-mediated amyloidosis (ATTR)...